I would like to think so. The

2022-04-30

I would like to think so. The flu + covid candidate has been reported many times to be performing well. The odd ball is the amount of time that FDA is taking to approve their vaccine. Many blames potenial conflict of interest within FDA and some says manufacturing issues in novavax. Production issues is likely resolved and now we have a timeline from FDA. And it is not like covid is going to be irrelavant soon, so we might still need periodic vaccination in the future.

Can Novavax Rebuild Investor Confidence? Analyst Weighs In

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

CatherineGunter
2022-04-30
CatherineGunter
Some experts suggest that people who are hesitant to take the Moderna or Pfizer-BioNTech shots might be more willing to accept the more conventional Novavax doses. It is also possible that a protein-based vaccine might work well as a booster to Pfizer or Moderna shots.
- bernardtayet:
  Agreed. Good view.
FranklinMorley
2022-04-30
FranklinMorley
Those vaccines are based on newer messenger RNA technology, while Novavax’s vaccine is protein-based. Protein-based vaccines have been used for decades and generally have a strong track record of safety and mild side effects.
CyrilDavy
2022-04-30
CyrilDavy
It is not clear what role the Novavax vaccine, if authorized, would play in the nation’s vaccination program.
Investboss
2022-04-30
Investboss
Like me
rhktrade
2022-04-30
rhktrade
ok nice
newtoUS
2022-04-30
newtoUS
ok

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":9069677511,"tweetId":"9069677511","gmtCreate":1651286414111,"gmtModify":1676534885129,"author":{"id":4100909250192760,"idStr":"4100909250192760","authorId":4100909250192760,"authorIdStr":"4100909250192760","name":"XLMM","avatar":"https://community-static.tradeup.com/news/5fd3a75ea7ccf88aca493e34c270e676","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":14,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>I would like to think so. The flu + covid candidate has been reported many times to be performing well. The odd ball is the amount of time that FDA is taking to approve their vaccine. Many blames potenial conflict of interest within FDA and some says manufacturing issues in novavax. Production issues is likely resolved and now we have a timeline from FDA. And it is not like covid is going to be irrelavant soon, so we might still need periodic vaccination in the future.</p></body></html>","htmlText":"<html><head></head><body><p>I would like to think so. The flu + covid candidate has been reported many times to be performing well. The odd ball is the amount of time that FDA is taking to approve their vaccine. Many blames potenial conflict of interest within FDA and some says manufacturing issues in novavax. Production issues is likely resolved and now we have a timeline from FDA. And it is not like covid is going to be irrelavant soon, so we might still need periodic vaccination in the future.</p></body></html>","text":"I would like to think so. The flu + covid candidate has been reported many times to be performing well. The odd ball is the amount of time that FDA is taking to approve their vaccine. Many blames potenial conflict of interest within FDA and some says manufacturing issues in novavax. Production issues is likely resolved and now we have a timeline from FDA. And it is not like covid is going to be irrelavant soon, so we might still need periodic vaccination in the future.","highlighted":1,"essential":1,"paper":1,"likeSize":14,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9069677511","repostId":2231291848,"repostType":2,"repost":{"id":"2231291848","kind":"news","pubTimestamp":1651459748,"share":"https://www.laohu8.com/m/news/2231291848?lang=&edition=full","pubTime":"2022-05-02 10:49","market":"us","language":"en","title":"Can Novavax Rebuild Investor Confidence? Analyst Weighs In","url":"https://stock-news.laohu8.com/highlight/detail?id=2231291848","media":"TipRanks","summary":"Pandemic tailwinds have been spirited away on the wind of change. Companies which thrived as Covid-1","content":"<div>\n<p>Pandemic tailwinds have been spirited away on the wind of change. Companies which thrived as Covid-19 concerns trumped any other global developments are now feeling the effect of its waning influence....</p>\n\n<a href=\"https://www.tipranks.com/news/article/can-novavax-rebuild-investor-confidence-with-a-strong-q1-showing-analyst-weighs-in/\">Web Link</a>\n\n</div>\n","source":"lsy1606183248679","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can Novavax Rebuild Investor Confidence? Analyst Weighs In</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan Novavax Rebuild Investor Confidence? Analyst Weighs In\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-02 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/article/can-novavax-rebuild-investor-confidence-with-a-strong-q1-showing-analyst-weighs-in/><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pandemic tailwinds have been spirited away on the wind of change. Companies which thrived as Covid-19 concerns trumped any other global developments are now feeling the effect of its waning influence....</p>\n\n<a href=\"https://www.tipranks.com/news/article/can-novavax-rebuild-investor-confidence-with-a-strong-q1-showing-analyst-weighs-in/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.tipranks.com/news/article/can-novavax-rebuild-investor-confidence-with-a-strong-q1-showing-analyst-weighs-in/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2231291848","content_text":"Pandemic tailwinds have been spirited away on the wind of change. Companies which thrived as Covid-19 concerns trumped any other global developments are now feeling the effect of its waning influence.This has been evident from the performance of ecommerce stocks, streamers and all manner of WFH names. Of course, coronavirus stocks - that segment which came into being as the pandemic took hold – are feeling the effect too.With the pandemic now on the backfoot in many parts of the world, the demand for Covid vaccines is dropping, a fact noted by B. Riley’s Mayank Mamtani.“The imbalance to supply & demand for these products has become particularly alarming, as already evidenced by JNJ 1Q earnings' guidance and anticipated 1Q earnings' commentary from AZN, BNTX/PFE, MRNA, REGN,” Mamtani explained.But more so than any of those companies, one of the pandemic era’s biggest stars has suffered the most from the shift in sentiment.Novavax (NVAX) shares are down 81% over the past 12 months, as the Maryland-based vaccine maker still hasn’t managed to get its Covid-19 across the finish line in the U.S. The company has yet to receive emergency use authorization (EUA) for its protein-adjuvanted shot.However, interestingly, while investors have evidently become impatient around the slow regulatory progress, as many developed nations ready for the transition to a post-pandemic world, Mamtani thinks Novavax remains “relatively the most protected from the generally bearish investor sentiment brewing for C-19 vaccine & therapeutics' peers.”But that could be dependent on how the anticipated ~mid-May Q1 print turns out. To get investors back on side, Mamtani expects Novavax to “reassure investors on the near-term and long-term strength of its recently established global vaccine biz.”By reiterating the FY22 revenue guidance of $4-5 billion, the company could take the first step in rebuilding investor confidence, with its adjuvanted protein-based platform “continuing to serve as a source of delivering diversified, multi-product portfolio for COVID, flu, malaria, and RSV.”That said, given the demand uncertainty, Mamtani has slashed his price target from $250 to $203. No need to get too forlorn – there’s still upside of 350% from current levels. Mamtani’s rating stays a Buy.The Street’s average target also offers plenty of returns; at $169.4, the figure represents potential one-year upside of ~276%. Overall, the analyst consensus rates this stock a Moderate Buy, based on 5 Buys vs. 2 Holds.","news_type":1},"isVote":1,"tweetType":1,"viewCount":169,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":388,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":101515474,"commentId":"101515474","gmtCreate":1651286567417,"gmtModify":1663248197741,"authorId":9000000000000657,"author":{"id":9000000000000657,"idStr":"9000000000000657","authorId":9000000000000657,"name":"CatherineGunter","avatar":"https://static.tigerbbs.com/3776235f8fbc22077e8df03b2522caf3","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9069677511,"objectIdStr":"9069677511","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"Some experts suggest that people who are hesitant to take the Moderna or Pfizer-BioNTech shots might be more willing to accept the more conventional Novavax doses. It is also possible that a protein-based vaccine might work well as a booster to Pfizer or Moderna shots.","text":"Some experts suggest that people who are hesitant to take the Moderna or Pfizer-BioNTech shots might be more willing to accept the more conventional Novavax doses. It is also possible that a protein-based vaccine might work well as a booster to Pfizer or Moderna shots.","html":"Some experts suggest that people who are hesitant to take the Moderna or Pfizer-BioNTech shots might be more willing to accept the more conventional Novavax doses. It is also possible that a protein-based vaccine might work well as a booster to Pfizer or Moderna shots.","likeSize":0,"commentSize":1,"subComments":[{"id":101551070,"commentId":"101551070","gmtCreate":1651463234675,"gmtModify":1663248346734,"authorId":3583377018896117,"author":{"id":3583377018896117,"idStr":"3583377018896117","authorId":3583377018896117,"name":"bernardtayet","avatar":"https://static.tigerbbs.com/43e8c1fc37a4bff2a94af98953cff267","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"60.30%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9069677511,"objectIdStr":"9069677511","type":1,"supId":101515474,"supIdStr":"101515474","prevId":0,"prevIdStr":"0","content":"Agreed. Good view.","text":"Agreed. Good view.","html":"Agreed. Good view."}],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":101515458,"commentId":"101515458","gmtCreate":1651286517518,"gmtModify":1663248196440,"authorId":9000000000000584,"author":{"id":9000000000000584,"idStr":"9000000000000584","authorId":9000000000000584,"name":"FranklinMorley","avatar":"https://static.tigerbbs.com/41438e43bc06f3d850c94c7d80eb56cf","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9069677511,"objectIdStr":"9069677511","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"Those vaccines are based on newer messenger RNA technology, while Novavax’s vaccine is protein-based. Protein-based vaccines have been used for decades and generally have a strong track record of safety and mild side effects.","text":"Those vaccines are based on newer messenger RNA technology, while Novavax’s vaccine is protein-based. Protein-based vaccines have been used for decades and generally have a strong track record of safety and mild side effects.","html":"Those vaccines are based on newer messenger RNA technology, while Novavax’s vaccine is protein-based. Protein-based vaccines have been used for decades and generally have a strong track record of safety and mild side effects.","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":101515461,"commentId":"101515461","gmtCreate":1651286535863,"gmtModify":1663248196938,"authorId":9000000000000641,"author":{"id":9000000000000641,"idStr":"9000000000000641","authorId":9000000000000641,"name":"CyrilDavy","avatar":"https://static.tigerbbs.com/fd67ba4a6ca5ca66b27af6afcce989dc","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9069677511,"objectIdStr":"9069677511","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"It is not clear what role the Novavax vaccine, if authorized, would play in the nation’s vaccination program.","text":"It is not clear what role the Novavax vaccine, if authorized, would play in the nation’s vaccination program.","html":"It is not clear what role the Novavax vaccine, if authorized, would play in the nation’s vaccination program.","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":101515637,"commentId":"101515637","gmtCreate":1651287111959,"gmtModify":1663248200240,"authorId":3575152837120760,"author":{"id":3575152837120760,"idStr":"3575152837120760","authorId":3575152837120760,"name":"Investboss","avatar":"https://static.itradeup.com/news/f3dee9e61855f88d9a8b006ca5513e3c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9069677511,"objectIdStr":"9069677511","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"Like me","text":"Like me","html":"Like me","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0},{"id":101515648,"commentId":"101515648","gmtCreate":1651287133674,"gmtModify":1663248200130,"authorId":3578967318304773,"author":{"id":3578967318304773,"idStr":"3578967318304773","authorId":3578967318304773,"name":"rhktrade","avatar":"https://static.tigerbbs.com/a27663c2a4d6be73c97c21238bc038fc","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9069677511,"objectIdStr":"9069677511","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"ok nice","text":"ok nice","html":"ok nice","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0},{"id":101515640,"commentId":"101515640","gmtCreate":1651287116716,"gmtModify":1663248200027,"authorId":3575929769091766,"author":{"id":3575929769091766,"idStr":"3575929769091766","authorId":3575929769091766,"name":"newtoUS","avatar":"https://static.tigerbbs.com/9b8dfb089132dd6830b3d50bd9ba1db2","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9069677511,"objectIdStr":"9069677511","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"ok","text":"ok","html":"ok","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/9069677511"}